The Global Healthcare Divorce: How US and EU Reforms Are Reshaping the Structure of Life Sciences Companies
8.21.2026
The life sciences industry is at a turning point. For years, healthcare regulation has focused on issues such as drug pricing, reimbursement disputes, fraud enforcement and compliance failures. Lately, it feels as though something larger is happening underneath the surface.
In both the United States and the European Union, regulators are beginning to question not just how healthcare companies behave, but how they are structured. In the U.S., lawmakers are challenging whether insurance companies and pharmacy benefit managers should also own pharmacies. Contrast that to the EU, where regulators are proposing to shorten the time drug manufacturers can block competitors from entering the market unless certain access requirements are met.
These changes in how governments think about complex markets like healthcare now feel more volatile instead of moderate.
The United States: A Surprising Challenge To Vertical Integration
For more than a decade, large healthcare companies have operated through vertically integrated models. Insurers have acquired pharmacy benefit managers. Pharmacy benefit managers have acquired specialty pharmacies. Some companies now control multiple steps of the drug distribution chain.
Until recently, most legal challenges to this model focused on antitrust enforcement or reimbursement disputes. Now, the Break Up Big Medicine Act would require certain insurers and pharmacy benefit managers to divest affiliated pharmacy operations.
This bill’s introduction marks a meaningful shift in tone. Congress is no longer asking whether integrated companies are complying with existing law. The question now seems to focus on whether certain business models should exist at all.
Why This Matters
If legislation were enacted requiring divestiture within a short time frame, the consequences would extend far beyond operational inconvenience.
Companies would need to consider important issues such as: (1) how to value assets under potential forced-sale conditions; (2) whether existing debt agreements restrict structural changes; (3) whether contracts with providers or pharmacies can be reassigned and (4) how state regulators would treat newly separated entities.
Even the possibility of mandatory divestiture can affect capital markets. Publicly traded companies may likely need to revisit risk disclosures in previous securities filings, while investors may reassess valuation assumptions previously tied to integrated business models.
The European Union: Changing the Rules on Exclusivity
At the same time, the European Union is pursuing a major reform of its pharmaceutical legislation. In April 2023, the European Commission proposed amendments to Directive 2001/83/EC, the EU’s core legal framework governing the approval and regulatory protection of medicines.[1]
One of the most significant proposed changes concerns regulatory data protection. Under the current system, drug manufacturers generally benefit from eight years during which generic competitors cannot rely on their clinical trial data, followed by additional market protection. This structure is often described as the “8+2+1” model.
The European Commission has proposed reducing the base data protection period from eight years to six years. If adopted in substantially similar form, this reduction would affect how companies calculate the effective commercial life of their products across the EU.
Conditional Extensions
The proposal would allow companies to regain some of the lost protection if they meet certain conditions. For example, additional protection may be available if:
- The product is made available across all EU member states within a defined time period.
- The medicine addresses an identified unmet medical need.
- The manufacturer complies with new transparency and supply requirements.
In practical terms, this means that exclusivity would no longer be automatic. It would depend in part on how broadly and how quickly a company brings its product to market.
It is important to note that these changes affect regulatory exclusivity, not patent duration. However, for business planning purposes, a shorter exclusivity window can have a significant impact on revenue projections, investment decisions and launch strategy.
For multinational companies, particularly smaller biotechnology firms, the requirement to launch across all 27 member states within a short time frame could present logistical and financial challenges. Pricing negotiations, reimbursement timelines and distribution infrastructure vary across countries, of which coordinating such complex logistics would take time and careful planning.
A Broader Shift
Although the U.S. and EU approaches differ, they are philosophically united in that regulators are no longer focusing solely on whether companies comply with rules. They are increasingly questioning whether certain business models produce outcomes consistent with public health goals.
In the U.S., the focus is on ownership and integration. In the EU, the focus is on how long companies can rely on regulatory protections before facing competition.
For lawyers in any practice area, this shift is worth noting. When regulators begin to revisit foundational issues such as ownership, exclusivity or market design, the ripple effects will extend far beyond what one can reasonably envision.
Implications for Boards and General Counsel
For companies operating across borders, these developments require careful planning.
Boards and general counsel may want to consider:
- How dependent the company’s financial model is on vertical integration.
- How changes in EU exclusivity periods could affect global launch sequencing.
- Whether product channels can survive sudden market shocks like tariffs.
- Whether securities disclosures adequately reflect regulatory uncertainty.
Why This Moment Feels Different
What makes this period distinct is not just the substance of the reforms, but the speed with which policymakers are pursuing them.
Healthcare regulation is entering a new phase. In the United States, lawmakers are considering whether vertically integrated healthcare conglomerates should be broken apart. In the European Union, regulators are proposing to shorten baseline regulatory protections while tying additional protection to access and supply obligations.
For lawyers advising clients in any sector touched by healthcare, the message is clear: Structural change is no longer theoretical. It is becoming part of the “normal” policy conversation.
Ron Lanton III is senior partner at Lanton, Lanton & Sosa Law.
Endnote:
[1] Proposal for a Directive of the European Parliament and of the Council on the Union Code Relating to Medicinal Products for Human Use, COM (2023) 192 final (Apr. 26, 2023).
